DHL Supply Chain has launched four new storage facilities around Australia.
The healthcare-grade facilities will store and manage inventory of pharmaceuticals, medical devices, vaccines, animal health, diagnostics, and consumer health products, to support the increasing demand for these products.
The additional capacity will also enable DHL to efficiently manage the storage and distribution of any upcoming Covid-19 vaccines.
The new facilities have a combined floor space of approximately 64,000sqm – equivalent to nine football fields – across the Sydney, Melbourne, Brisbane, and Perth metropolitan areas.
This investment includes more than 9,000sqm of DHL’s cold-chain operations to support the success of critically important cold chain products around Australia, which must be stored in temperatures ranging from 2 to 8-degree celsius.
DHL Supply Chain also has proprietary packaging solutions designed specifically for pharmaceutical products to ensure health supplies are delivered in the perfect condition.
Saul Resnick, CEO of DHL Supply Chain, Australia and New Zealand, says: “The life sciences and healthcare industry is one of the most heavily regulated industries, and DHL is the only 3PL in Australia to provide solutions that meet current global regulations.
“We have seen a growing interest in our industry-leading cold storage facilities which in turn, drives better outcomes for the storage and distribution of healthcare products. Increasingly, we have also seen a growing appetite for local distribution centres to be an ongoing part of global supply chains.”
In addition to the new facilities, DHL Supply Chain will also invest in a new multi-million dollar transport management system and national control tower, to support more efficient consignment planning and offer customers greater visibility of their deliveries.
Further plans are underway to introduce a cold chain automation picking and packing solution which will drive compliant, and efficient processes to safeguard future demands of the industry in the growing segment of pharmaceutical supply.
This project will be the first of its kind in Australia, based in New South Wales.
